<DOC>
	<DOCNO>NCT00710710</DOCNO>
	<brief_summary>The trial conduct order evaluate efficacy , safety pharmacokinetics BI 2536 treatment unresectable advanced pancreatic cancer first line second line therapy . A secondary aim identify suitable dosage regimen phase II III clinical programme BI 2536 . To achieve objective , two dosage regimen compare patient receive first line therapy .</brief_summary>
	<brief_title>Open , Randomized Phase II Trial Investigate Efficacy Safety PLK-1 Inhibitor BI 2536 Patients With Advanced , Unresectable Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>1. male female patient age 18 year old 2. patient confirm diagnosis unresectable , either locally advanced metastatic , ductal adenocarcinoma pancreas 3. patient either chemona誰ve ( first line cohort ) , present progressive disease first line chemotherapy gemcitabine base regimen ( second line cohort ) 4 . Karnofsky performance status 多 70 % first line cohort , Karnofsky performance status 多 50 % second line cohort 5. patient least one measurable tumour lesion accurately measure magnetic resonance imaging ( MRI ) , compute tomography ( CT ) least one dimension ( long diameter record ) 6. life expectancy least three month 7. patient must give write informed consent consistent guideline international conference harmonisation good clinical practice ( ICHGCP ) well local legislation 1. prior adjuvant chemotherapy ( first line cohort ) 2. ampullary carcinoma pancreas 3. hypersensitivity trial drug excipients 4. persistence toxicity prior anti cancer therapy deem clinically relevant 5. know second malignancy require therapy 6. brain metastasis symptomatic require therapy 7. absolute neutrophil count less 1.500/mm3 8. platelet count less 100.000/mm3 9. haemoglobin less 9 mg/dl 10. aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) great 2.5 time upper limit normal , AST ALT great 5 time upper limit normal case know liver metastases 11. bilirubin great 3.0 mg/dl ( &gt; 52 多mol/l , SI unit equivalent ) adequate drainaging measure ( case obstructive jaundice ) 12. serum creatinine great 2.0 mg/dl 13. concomitant intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness social situation would limit compliance trial requirement consider relevant evaluation efficacy safety trial drug 14. radiotherapy within past four week prior treatment trial drug 15. hormone immunotherapy therapy biologic response modifier within past four week 16. treatment investigational drug within past four week 17. men woman sexually active unwilling use medically acceptable method contraception ( e.g . abstinence , condom spermicidal coating , diaphragm spermicidal coating , oral contraceptive , progesterone implant , sterilisation ) trial 18. pregnancy lactation 19. patient unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>